Abivax (ABVX) Debt to Equity (2023 - 2025)

Abivax (ABVX) recorded quarterly Debt to Equity of $0.07 in Q4 2025, up 7.36% quarter-over-quarter from $0.07 in Q3 2025, and down 93.63% on a YoY basis from $1.11 in Q4 2024.

Abivax (ABVX) Debt to Equity (2023 - 2025) Analysis & Trends

Abivax's Debt to Equity history runs 3 years deep, the most recent figure standing at $0.07 for Q4 2025.

  • In Q4 2025, Debt to Equity fell 93.63% year-over-year to $0.07; the TTM figure through Dec 2025 stood at $0.07 (down 93.63% YoY), while the FY2025 annual figure was $0.07, down 93.63% from the prior year.
  • Debt to Equity was $0.07 for Q4 2025 at Abivax, up from $0.07 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.11 in Q4 2024 to a low of -$10.5 in Q1 2025.
  • Historically, Debt to Equity has averaged -$1.46 across 3 years, with a median of $0.07 in 2025.
  • The sharpest annual moves came in 2024 and 2025: Debt to Equity jumped 402.1% in 2024, then sank 537.13% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.22 in 2023, then surged by 402.1% to $1.11 in 2024, then plunged by 93.63% to $0.07 in 2025.
  • The last three Debt to Equity figures came in at $0.07 (Q4 2025), $0.07 (Q3 2025), and -$1.55 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn -
9 Abivax 94.26 Bn 94.26 Bn - -
10 Regeneron Pharmaceuticals 66.09 Bn 57.33 Bn 3.31 Bn 0.06

Historic Data

Download Data
DateValue
Dec 31, 2025 0.07
Sep 30, 2025 0.07
Jun 30, 2025 -1.55
Mar 31, 2025 -10.50
Dec 31, 2024 1.11
Jun 30, 2024 0.35
Dec 31, 2023 0.22